Brokerage firm UBS Downgrades its rating on Neos Therapeutics Inc(NEOS). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by the stock financial advisor at UBS was issued on Mar 20, 2017 in a research report to their Investors and Clients.
Neos Therapeutics Inc (NEOS) shares turned negative on Wednesdays trading session with the shares closing down -0.1 points or -1.50% at a volume of 2,47,842. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $6.8. The peak price level was also seen at $6.8 while the days lowest was $6.4. Finally the shares closed at $6.55. The 52-week high of the shares is $11.5 while the 52-week low is $4.85. According to the latest information available, the market cap of the company is $148 M.
Neos Therapeutics Inc(NEOS) last announced its earnings results on Mar 14, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $3.503M. Analysts had an estimated revenue of $3.760M. Earnings per share were $-1.14. Analysts had estimated an EPS of $-1.36.
Several Insider Transactions has been reported to the SEC. On Aug 31, 2016, Bryant Fong (director) purchased 1,500 shares at $6.54 per share price.Also, On Aug 25, 2016, Richard I Eisenstadt (CFO) purchased 3,710 shares at $6.82 per share price.On Jun 14, 2016, Juergen Martens (Chief Tech/Operations Officer) purchased 10,000 shares at $9.90 per share price, according to the Form-4 filing with the securities and exchange commission.
Neos Therapeutics Inc. is a pharmaceutical company develops manufactures and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The Companys product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It manufactures and markets generic Tussionex a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie Texas.